Global Cholera Vaccines Market By Product (Dukoral, Shanchol, Vaxchora, Others Products), By Type (Whole Cell V. Cholerae O1 with Recombinant B-Subunit, Killed Oral O1 and O139), By End-Users (Hospitals and Clinics, Research and Academic Laboratories, Others), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2023-2032
-
37400
-
June 2023
-
179
-
-
This report was compiled by Trishita Deb Trishita Deb is an experienced market research and consulting professional with over 7 years of expertise across healthcare, consumer goods, and materials, contributing to over 400 healthcare-related reports. Correspondence Team Lead- Healthcare Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
-
Quick Navigation
Report Overview
Global Cholera Vaccines Market size is expected to be worth around USD 13.8 Mn by 2032 from USD 5.0 Mn in 2022, growing at a CAGR of 11.0% during the forecast period from 2023 to 2032.
The multifaceted nature of the global cholera vaccines market incorporates a plethora of intricate elements, evidencing its central role in the development, production, and distribution of vaccines to combat and mitigate the dangers of cholera. Cholera, an abhorrent infectious disease caused by the threatening Vibrio cholera bacterium, is primarily transmitted through water and food that have been tainted with toxins. Failure to address this dangerous disease in a timely and effective manner can result in dire consequences, including debilitating dehydration and even premature death.
A primary objective of the cholera vaccines market is to provide safe and effective vaccines to individuals facing the impending threat of cholera, especially in developing countries with limited access to potable water and adequate sanitation facilities.
The cholera vaccine market, imbued with a sacred duty of public welfare, performs an indispensable role in reducing the incidence of cholera and simultaneously saving countless lives. Moreover, prudent investments in the field of cholera vaccine development have the potential to foster remarkable technological advances and innovative discoveries that could have repercussions throughout the entire medical landscape.
Oral cholera vaccines (OCVs) represent a remarkable advancement in this field, exemplifying superior efficacy, easy distribution because they do not require refrigeration and undeniably substantial contributions to the reduction of cholera transmission.
As a result of substantial investments from government agencies, non-profit organizations, and major pharmaceutical corporations, the cholera vaccines market has witnessed a proliferation of commercially available vaccines. Some charitable organizations have deftly woven cholera vaccination into the fabric of their humanitarian efforts, especially in regions beset by natural calamities or virulent outbreaks.
Constant advancements in the fields of research and technology are anticipated to impel the market for cholera vaccines along an inexorable growth curve. In the not-too-distant future, the demand for cholera vaccines may ostensibly decline as the global population obtains access to more hygienic water sources and better sanitation infrastructure.
Unquestionably, the pharmaceutical industry, with its colossal presence, occupies a prominent position in the landscape of the cholera vaccines market, having made substantial investments in vaccine development and production. In addition, non-profit organizations and government agencies exert influence, bolstering the market's momentum with the commendable aim of improving health outcomes.
The ethical and moral dimensions that permeate the cholera vaccine market cannot be emphasized, as they continue to be inextricably woven into its very structure. Among these considerations, the urgent necessity of ensuring equitable access to vaccines, and giving priority to those with the greatest need, is paramount. Simultaneously, the dissemination of accurate and impartial information while avoiding potential conflicts of interest acquires a central position in this ethical discourse.
Driving factors
Cholera Vaccine Market Booms as Demand Skyrockets Due to Increasing Disease Awareness
The Global Cholera Vaccines Market is comprised of ongoing cholera eradication initiatives in various regions. People are now more of the significance of cholera prevention and vaccination due to the rise in disease awareness and education programs. This has increased demand for cholera vaccines and stimulated market expansion.
Advances in Vaccine Technologies Drive Cholera Vaccine Growth
Continual advances in vaccine technologies and formulations are a further factor that drives the market. The efficacy and safety of cholera vaccines have improved significantly as a result of increased research in this field. Governments throughout the world are also promoting the use of vaccines and facilitating their accessibility.
Potential Changes in Regulation Cholera Vaccine Faces Challenges
However, there may be regulatory changes that could affect the market for cholera vaccines. This may be the result of government policies, healthcare system changes, or other external factors. It is essential for manufacturers and suppliers to monitor these changes and take the necessary steps to mitigate risks and maintain business continuity.
Cholera Vaccine Could Be Revolutionized and Emerging Technologies
Emerging technologies such as DNA vaccines, mRNA vaccines, and others may have an effect on the market in the future years. These technologies have demonstrated promising results in clinical trials and have the potential to revolutionize the development and administration of vaccines.
The Cholera Vaccine Market Competitive Landscape Faces Disruption
There may also be potential disruptors in the cholera vaccines market competitive landscape. This may be the result of new entrants, mergers and acquisitions, a shift in market dynamics, or other factors. Companies on the market must be adaptive and flexible in order to remain competitive.
Restraining Factors
Cholera Vaccine Market Growth Is Hampered by Limited Access and Cost
The market for cholera vaccines has been hindered by a number of significant restraining factors. These include limited vaccine accessibility, storage/transportation difficulties, and vaccine reluctance. The limited availability of vaccines is a significant factor affecting the cholera vaccine market. Due to the high cost of production, the insufficient supply of the vaccine, and the lack of awareness in many developing nations, cholera vaccines are not readily accessible to everyone.
Overcoming Vaccine Inaccessibility Key Cholera Vaccine Steps
To address the issue of limited vaccine access, pharmaceutical companies must develop affordable and readily available cholera vaccines. Governments also have a role to play by providing funding to companies that develop vaccines and ensuring that all citizens, including those in remote or rural areas, have access to the vaccine.
Distribution of Cholera Vaccine Overcoming Storage and Transportation Challenges
Cholera vaccines must be stored within a particular temperature range in order to maintain their efficacy. In many developing nations, there is a lack of proper storage facilities and transportation systems that can maintain the required vaccine temperature range. This has caused vaccines to leak, resulting in a significant decrease in the vaccine supply.
Increasing Cholera Vaccine Demand by Addressing Vaccine Reluctance
Investing in the provision of proper storage and transportation facilities is required to address this issue. Pharmaceutical companies that manufacture cholera vaccines should collaborate with government agencies and non-governmental organizations (NGOs) to develop proper storage and transportation facilities in remote and rural areas.
Revenue Decline The Cholera Vaccine Market Faces Obstacles from Uncertain Customers
The adoption of cholera vaccines is being significantly hampered by vaccine hesitancy. Due to skepticism regarding the safety and efficacy of vaccines, individuals avoid receiving them. This has resulted in a decline in demand for vaccines, resulting in a decline in cholera vaccine market revenue.
By Product Analysis
Cholera is a serious waterborne disease caused by the bacterium Vibrio cholerae. If left untreated, the disease can cause severe dehydration and mortality within hours. In recent years, the global market for cholera vaccines has increased steadily. Recent research findings indicate that, among the numerous market segments, the Dukoral Segment is the most dominant.
Dukoral is a vaccine that provides protection against both cholera and an E. coli strain that can induce traveler's diarrhea. This vaccine is a liquid suspension that must be mixed with Sodium bicarbonate solution prior to administration. It consists of heat-inactivated whole V. cholerae O1 bacteria and recombinant B-subunit (rCTB) of the V. cholera toxin. This vaccine is approved for use in adults and children older than two years and is regarded as a safe and effective method of prevention. In the foreseeable future, the Dukoral Segment will continue to dominate the global cholera vaccines market.
The constant expansion of the global cholera vaccines market can be attributed to the economic growth of developing nations. As economies grow, people gain access to improved sanitation and pure water, which reduces the incidence of cholera. However, epidemics may still occur in areas with inadequate water and sanitation. Consequently, the demand for cholera vaccines is likely to rise in these regions, particularly as disease awareness and the availability of prevention tools increase.
Due to its dual efficacy against V. cholerae O1 and E. coli, the Dukoral vaccine controls the global cholera vaccine market. This combination has enhanced the vaccine's value proposition, and more individuals are willing to pay a premium for it. Additionally, the ease of administration through oral dosing facilitates its use, particularly in areas with limited resources and limited access to healthcare. Dukoral's high efficacy and low incidence of adverse reactions also contribute to its popularity.
By Type Analysis
In the market for cholera vaccines, the Whole Cell V. Cholerae O1 with Recombinant B Subunit vaccine is also gaining ground. This vaccine is manufactured using recombinant DNA technology and a heat-inactivated strain of V. cholera O1. The vaccine can be administered either intravenously or orally, making its use convenient.
Similar to Dukoral, it is anticipated that the use of Whole Cell V. Cholerae O1 with Recombinant B-Subunit Segment will increase in regions experiencing economic growth. As countries such as India, Bangladesh, and Nigeria continue to develop, it is anticipated that the incidence of cholera will decrease. However, preventative measures such as vaccination are required to eradicate the disease entirely.
Whole Cell V. Cholerae O1 with Recombinant B-Subunit Segment is acquiring popularity because it provides immunity against V. cholera O1 and, similar to Dukoral, has a low incidence of adverse events. Additionally, more people are likely to take the oral vaccine than the injectable vaccine, which has contributed to the expansion of this market segment.
By End-Users Analysis
The Hospitals and Clinics Segment dominates the market for cholera vaccines. This is due to the fact that vaccines are primarily administered in hospitals and clinics. Governments and international health organizations also purchase and distribute large quantities of vaccines, with hospitals and clinics being the primary recipients. In these facilities, the demand for cholera vaccines is driven by high accessibility, assurances of quality, and dependability.
As more developing nations invest in their healthcare infrastructure, the demand for cholera vaccines in hospitals and clinics will rise. Governments and non-government organizations have also played a significant role in increasing vaccination rates in these facilities through vaccination campaigns.
The primary driver of the high demand for cholera vaccines in hospitals and clinics is the need for prevention. This awareness of the disease and the significance of vaccination is expected to continue. In addition, rising confidence in the healthcare system has increased the number of individuals who seek vaccination services in hospitals and clinics.
Key Market Segments
By Product
- Dukoral
- Shanchol
- Vaxchora
- Others Products
By Type
- Whole Cell V. Cholerae O1 with Recombinant B-Subunit
- Killed Oral O1 and O139
By End-Users
- Hospitals and Clinics
- Research and Academic Laboratories
- Others
Growth Opportunity
Cholera Vaccines Drive Remarkable Market Growth as Outbreaks Continue
Cholera, an acute diarrheal disease, is responsible for a number of global epidemics, which primarily affect vulnerable populations in impoverished regions lacking access to clean water and sanitation. Oral cholera vaccines (OCVs) are regarded as the most efficient method for preventing cholera outbreaks. In recent years, the market for cholera vaccines has experienced remarkable growth as a result of several initiatives to expand vaccination programs, make vaccines more affordable and heat-stable, and integrate vaccination campaigns with water and sanitation initiatives.
Expanding Global Vaccination Programs to Combat Cholera Outbreaks
The expansion of vaccination programs worldwide is one of the primary growth drivers of the global cholera vaccines market. As part of an integrated cholera control strategy, the World Health Organization (WHO) endorsed the use of oral cholera vaccines (OCVs) in cholera-endemic regions in 2013.
Cholera Vaccine Revolutionized by Affordability and Heat Stability
In the market for cholera vaccines globally, affordability and heat resistance have been significant concerns. Cholera-endemic regions are typically located in low-income countries with limited resources, making costly vaccines difficult to afford. In addition, OCVs typically necessitate refrigeration, which can be problematic in regions where electricity and cold chain infrastructure are unreliable.
Cholera Vaccines Are Now Affordable and Heat-Stable Thanks to Innovative Solutions:
Several initiatives have been implemented to make OCVs more affordable and heat-resistant in response to these concerns. The Gavi Alliance, a public-private partnership that aims to improve access to vaccines for children in low-income countries, has funded OCV campaigns in a number of countries. Additionally, the Serum Institute of India has developed a heat-stable version of the OCV that can withstand high temperatures and does not require refrigeration. This has made remote areas more accessible and transportable.
Integration of Water and Vaccination Efforts Is Crucial for Cholera Control:
The integration of vaccination campaigns with water, sanitation, and hygiene efforts is a further growth driver for the global cholera vaccines market. Cholera is typically transmitted through contaminated water and food; therefore, enhancing water and sanitation infrastructure is essential for preventing outbreaks. Vaccination campaigns can also play an important role in preventing cholera outbreaks, but they must be conducted in tandem with water and sanitation initiatives to have an enduring effect.
Latest Trends
Rapid Growth in the Global Cholera Vaccines Market Caused by Key Trends
The Global Cholera Vaccines Market is expanding quickly as a result of significant market trends like the development of oral cholera vaccines, single-dose formulations, mass vaccination during outbreaks, and research into next-generation vaccines. Cholera is a severe diarrheal disease that is caused by the bacterium Vibrio cholerae.
Innovative Cholera Oral Vaccines Transform Cholera Control Efforts
In the struggle against cholera, the development of Oral Cholera Vaccines has been a significant advancement. OCV is a safe and efficacious vaccine that offers up to two years of cholera protection. Oral administration of the OCV is possible as either a two-dose or a single-dose regimen. During cholera epidemics, the single-dose formulation is strongly recommended. In cholera-endemic regions, the World Health Organization recommends using OCV to prevent and control outbreaks. Consequently, the global demand for OCV is increasing.
On the Cholera Vaccines Market, Single-Dose Formulations Gain Momentum
Single-dose formulations are gaining popularity due to their efficacy and simplicity of administration. Single-dose vaccines are preferred over multiple-dose vaccines because they offer earlier protection and a simpler vaccination schedule. In addition, single-dose vaccines reduce the need for healthcare personnel, which is crucial in areas with limited resources where the majority of cholera cases are reported.
Mass Vaccination During Cholera Outbreaks is Crucial
Another important trend in the global cholera vaccines market is mass vaccination during outbreaks. When a cholera outbreak occurs, it is crucial to vaccinate the afflicted population as quickly as possible to prevent the disease from spreading. Mass vaccination can lessen the severity and duration of a cholera outbreak, prevent new cases, and save lives.
Research on Next-Generation Vaccines Transforms the Fight against Cholera
Research into next-generation vaccines is a significant market driver for cholera vaccines. The next iteration of cholera vaccines is currently in development, and they offer significant advantages over existing vaccine options. The vaccines of the next generation are more potent, longer-lasting, and can be administered via alternative routes such as aerosol or nasal spray. Given the increasing industry antibiotics resistance of the Vibrio cholera bacterium, the development of next-generation vaccines is crucial.
Regional Analysis
Europe Dominates the Cholera Vaccines Market. In recent years, concerns about the spread of cholera, a bacterial infection that affects the small intestine, have increased. An estimated 4 million cases of cholera occur annually on a global scale, resulting in between 21,000 and 143,000 deaths.
Cholera is predominantly transmitted through contaminated food and water. The World Health Organization (WHO) estimates that up to 80% of cholera cases can be prevented through measures such as access to clean water and sanitation, but vaccination continues to be an essential weapon in the fight against the disease.
The killed whole-cell vaccine was created in the 1940s and is therefore the elder of the two. It is produced by killing cholera bacteria and then using the deceased bacteria to stimulate the immune system. The vaccine is administered in two doses, separated by a few weeks, and provides protection for up to two years. In regions where cholera is endemic, the slain whole-cell vaccine is utilized more frequently than in regions where cholera outbreaks are intermittent.
The oral cholera vaccine, on the other hand, was developed in the 1990s and is a more recent vaccine. It is composed of attenuated, live cholera bacteria and is administered orally in one or two dosages. The vaccine provides protection for up to five years and is typically administered in response to outbreaks, such as cholera outbreaks.
Europe dominates the market for cholera vaccines for numerous reasons. First, Europe is home to a number of the world's leading vaccine manufacturers, such as GlaxoSmithKline and Sanofi Pasteur. These companies have developed and manufactured cholera vaccines for many years and possess a multitude of knowledge and experience in the field.
Second, Europe is home to numerous prestigious research institutions that are actively engaged in the development of new and enhanced cholera vaccines. For instance, the European Vaccine Initiative is a leading organization that works to support the development of new cholera vaccines.
Thirdly, Europe has a robust regulatory framework for vaccines that ensures their safety, efficacy, and high quality. The European Medicines Agency (EMA) is the regulatory body tasked with approving vaccines in the European Union (EU) and ensuring that they satisfy the highest safety and efficacy standards.
Key Regions and Countries
North America
- US
- Canada
- Mexico
Western Europe
- Germany
- France
- The UK
- Spain
- Italy
- Portugal
- Ireland
- Austria
- Switzerland
- Benelux
- Nordic
- Rest of Western Europe
Eastern Europe
- Russia
- Poland
- The Czech Republic
- Greece
- Rest of Eastern Europe
APAC
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- Indonesia
- Malaysia
- Philippines
- Singapore
- Thailand
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Colombia
- Chile
- Argentina
- Costa Rica
- Rest of Latin America
Middle East & Africa
- Algeria
- Egypt
- Israel
- Kuwait
- Nigeria
- Saudi Arabia
- South Africa
- Turkey
- United Arab Emirates
- Rest of MEA
Key Players Analysis
The global cholera vaccines market is a rapidly expanding industry that is essential in the battle against cholera, a severe bacterial infection that affects millions of people annually. In order to provide life-saving vaccines to populations at risk of contracting the disease, the key players in this market are crucial.
With its Dukoral vaccine, GSK (GlaxoSmithKline) is one of the leading players in the global cholera vaccines market. This vaccine is efficacious against cholera caused by both the Ogawa and Inaba serotypes and is approved for use in over sixty countries. Sanofi Pasteur is another significant player with its Shanchol vaccine. This vaccine has been approved for use in India and is undergoing testing in additional developing countries.
PaxVax, which manufactures the Vaxchora vaccine, and Bharat Biotech, which produces the Cholera Vaccine Shanchol, are two additional key players in the global cholera vaccines market. There are also a number of lesser players on the market, including EuBiologics, Vietnam Vaccine JSC, and Shanghai Institute of Biological Products.
Top Key Players in Cholera Vaccines Market
- GSK plc (U.K.)
- Valneva SE. (France)
- EMERGENT (U.S.)
- Astellas Pharma Inc.(Japan)
- Sanofi (France)
- EUBIOLOGICS CO., LTD (South Korea)
- Johnson & Johnson Services Inc. (India)
- Celldex Therapeutics. (U.S.)
- Merck & Co., Inc. (U.S.)
- PaxVax
- Other Key Players
Recent Development
- In 2022, The Food and Drug Administration (FDA) granted CVD 103-HgR a license to be used in the United States.
- In 2021, A study published in Nature Microbiology demonstrated that the CVD 103-HgR vaccine was 85 percent effective at preventing cholera in adults.
- In 2020, The WHO advised cholera-endemic countries to incorporate Shanchol into their national immunization programs.
- In 2019, A study published in The Lancet demonstrated that a single dose of Shanchol is 65 percent effective in preventing cholera for up to five years.
- In 2018, Shanchol, an oral cholera vaccine developed by the Serum Institute of India, was prequalified by The World Health Organization (WHO).
Report Scope:
Report Features Description Market Value (2022) USD 5.0 Mn Forecast Revenue (2032) USD 13.8 Mn CAGR (2023-2032) 11.00% Base Year for Estimation 2022 Historic Period 2016-2022 Forecast Period 2023-2032 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Product (Dukoral, Shanchol, Vaxchora, Others Products), By Type (Whole Cell V. Cholerae O1 with Recombinant B-Subunit, Killed Oral O1 and O139), By End-Users (Hospitals and Clinics, Research and Academic Laboratories, Others) Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA Competitive Landscape GSK plc (U.K.), Valneva SE. (France), EMERGENT (U.S.), Astellas Pharma Inc.(Japan), Sanofi (France), EUBIOLOGICS CO., LTD (South Korea), Johnson & Johnson Services Inc. (India), Celldex Therapeutics. (U.S.), Merck & Co., Inc. (U.S.), Other Key Players, Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) -
- 1. Executive Summary
- 1.1. Definition
- 1.2. Taxonomy
- 1.3. Research Scope
- 1.4. Key Analysis
- 1.5. Key Findings by Major Segments
- 1.6. Top strategies by Major Players
- 2. Global Cholera Vaccines Market Overview
- 2.1. Cholera Vaccines Market Dynamics
- 2.1.1. Drivers
- 2.1.2. Opportunities
- 2.1.3. Restraints
- 2.1.4. Challenges
- 2.2. Macro-economic Factors
- 2.3. Regulatory Framework
- 2.4. Market Investment Feasibility Index
- 2.5. PEST Analysis
- 2.6. PORTER’S Five Force Analysis
- 2.7. Drivers & Restraints Impact Analysis
- 2.8. Industry Chain Analysis
- 2.9. Cost Structure Analysis
- 2.10. Marketing Strategy
- 2.11. Russia-Ukraine War Impact Analysis
- 2.12. Opportunity Map Analysis
- 2.13. Market Competition Scenario Analysis
- 2.14. Product Life Cycle Analysis
- 2.15. Opportunity Orbits
- 2.16. Manufacturer Intensity Map
- 2.17. Major Companies sales by Value & Volume
- 2.1. Cholera Vaccines Market Dynamics
- 3. Global Cholera Vaccines Market Analysis, Opportunity and Forecast, 2016-2032
- 3.1. Global Cholera Vaccines Market Analysis, 2016-2021
- 3.2. Global Cholera Vaccines Market Opportunity and Forecast, 2023-2032
- 3.3. Global Cholera Vaccines Market Analysis, Opportunity and Forecast, By By Product, 2016-2032
- 3.3.1. Global Cholera Vaccines Market Analysis by By Product: Introduction
- 3.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Product, 2016-2032
- 3.3.3. Dukoral
- 3.3.4. Shanchol
- 3.3.5. Vaxchora
- 3.3.6. Others Products
- 3.4. Global Cholera Vaccines Market Analysis, Opportunity and Forecast, By By Type, 2016-2032
- 3.4.1. Global Cholera Vaccines Market Analysis by By Type: Introduction
- 3.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Type, 2016-2032
- 3.4.3. Whole Cell V. Cholerae O1 with Recombinant B-Subunit
- 3.4.4. Killed Oral O1 and O139
- 3.5. Global Cholera Vaccines Market Analysis, Opportunity and Forecast, By By End-Users, 2016-2032
- 3.5.1. Global Cholera Vaccines Market Analysis by By End-Users: Introduction
- 3.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-Users, 2016-2032
- 3.5.3. Hospitals and Clinics
- 3.5.4. Research and Academic Laboratories
- 3.5.5. Others
- 4. North America Cholera Vaccines Market Analysis, Opportunity and Forecast, 2016-2032
- 4.1. North America Cholera Vaccines Market Analysis, 2016-2021
- 4.2. North America Cholera Vaccines Market Opportunity and Forecast, 2023-2032
- 4.3. North America Cholera Vaccines Market Analysis, Opportunity and Forecast, By By Product, 2016-2032
- 4.3.1. North America Cholera Vaccines Market Analysis by By Product: Introduction
- 4.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Product, 2016-2032
- 4.3.3. Dukoral
- 4.3.4. Shanchol
- 4.3.5. Vaxchora
- 4.3.6. Others Products
- 4.4. North America Cholera Vaccines Market Analysis, Opportunity and Forecast, By By Type, 2016-2032
- 4.4.1. North America Cholera Vaccines Market Analysis by By Type: Introduction
- 4.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Type, 2016-2032
- 4.4.3. Whole Cell V. Cholerae O1 with Recombinant B-Subunit
- 4.4.4. Killed Oral O1 and O139
- 4.5. North America Cholera Vaccines Market Analysis, Opportunity and Forecast, By By End-Users, 2016-2032
- 4.5.1. North America Cholera Vaccines Market Analysis by By End-Users: Introduction
- 4.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-Users, 2016-2032
- 4.5.3. Hospitals and Clinics
- 4.5.4. Research and Academic Laboratories
- 4.5.5. Others
- 4.6. North America Cholera Vaccines Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 4.6.1. North America Cholera Vaccines Market Analysis by Country : Introduction
- 4.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 4.6.2.1. The US
- 4.6.2.2. Canada
- 4.6.2.3. Mexico
- 5. Western Europe Cholera Vaccines Market Analysis, Opportunity and Forecast, 2016-2032
- 5.1. Western Europe Cholera Vaccines Market Analysis, 2016-2021
- 5.2. Western Europe Cholera Vaccines Market Opportunity and Forecast, 2023-2032
- 5.3. Western Europe Cholera Vaccines Market Analysis, Opportunity and Forecast, By By Product, 2016-2032
- 5.3.1. Western Europe Cholera Vaccines Market Analysis by By Product: Introduction
- 5.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Product, 2016-2032
- 5.3.3. Dukoral
- 5.3.4. Shanchol
- 5.3.5. Vaxchora
- 5.3.6. Others Products
- 5.4. Western Europe Cholera Vaccines Market Analysis, Opportunity and Forecast, By By Type, 2016-2032
- 5.4.1. Western Europe Cholera Vaccines Market Analysis by By Type: Introduction
- 5.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Type, 2016-2032
- 5.4.3. Whole Cell V. Cholerae O1 with Recombinant B-Subunit
- 5.4.4. Killed Oral O1 and O139
- 5.5. Western Europe Cholera Vaccines Market Analysis, Opportunity and Forecast, By By End-Users, 2016-2032
- 5.5.1. Western Europe Cholera Vaccines Market Analysis by By End-Users: Introduction
- 5.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-Users, 2016-2032
- 5.5.3. Hospitals and Clinics
- 5.5.4. Research and Academic Laboratories
- 5.5.5. Others
- 5.6. Western Europe Cholera Vaccines Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 5.6.1. Western Europe Cholera Vaccines Market Analysis by Country : Introduction
- 5.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 5.6.2.1. Germany
- 5.6.2.2. France
- 5.6.2.3. The UK
- 5.6.2.4. Spain
- 5.6.2.5. Italy
- 5.6.2.6. Portugal
- 5.6.2.7. Ireland
- 5.6.2.8. Austria
- 5.6.2.9. Switzerland
- 5.6.2.10. Benelux
- 5.6.2.11. Nordic
- 5.6.2.12. Rest of Western Europe
- 6. Eastern Europe Cholera Vaccines Market Analysis, Opportunity and Forecast, 2016-2032
- 6.1. Eastern Europe Cholera Vaccines Market Analysis, 2016-2021
- 6.2. Eastern Europe Cholera Vaccines Market Opportunity and Forecast, 2023-2032
- 6.3. Eastern Europe Cholera Vaccines Market Analysis, Opportunity and Forecast, By By Product, 2016-2032
- 6.3.1. Eastern Europe Cholera Vaccines Market Analysis by By Product: Introduction
- 6.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Product, 2016-2032
- 6.3.3. Dukoral
- 6.3.4. Shanchol
- 6.3.5. Vaxchora
- 6.3.6. Others Products
- 6.4. Eastern Europe Cholera Vaccines Market Analysis, Opportunity and Forecast, By By Type, 2016-2032
- 6.4.1. Eastern Europe Cholera Vaccines Market Analysis by By Type: Introduction
- 6.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Type, 2016-2032
- 6.4.3. Whole Cell V. Cholerae O1 with Recombinant B-Subunit
- 6.4.4. Killed Oral O1 and O139
- 6.5. Eastern Europe Cholera Vaccines Market Analysis, Opportunity and Forecast, By By End-Users, 2016-2032
- 6.5.1. Eastern Europe Cholera Vaccines Market Analysis by By End-Users: Introduction
- 6.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-Users, 2016-2032
- 6.5.3. Hospitals and Clinics
- 6.5.4. Research and Academic Laboratories
- 6.5.5. Others
- 6.6. Eastern Europe Cholera Vaccines Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 6.6.1. Eastern Europe Cholera Vaccines Market Analysis by Country : Introduction
- 6.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 6.6.2.1. Russia
- 6.6.2.2. Poland
- 6.6.2.3. The Czech Republic
- 6.6.2.4. Greece
- 6.6.2.5. Rest of Eastern Europe
- 7. APAC Cholera Vaccines Market Analysis, Opportunity and Forecast, 2016-2032
- 7.1. APAC Cholera Vaccines Market Analysis, 2016-2021
- 7.2. APAC Cholera Vaccines Market Opportunity and Forecast, 2023-2032
- 7.3. APAC Cholera Vaccines Market Analysis, Opportunity and Forecast, By By Product, 2016-2032
- 7.3.1. APAC Cholera Vaccines Market Analysis by By Product: Introduction
- 7.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Product, 2016-2032
- 7.3.3. Dukoral
- 7.3.4. Shanchol
- 7.3.5. Vaxchora
- 7.3.6. Others Products
- 7.4. APAC Cholera Vaccines Market Analysis, Opportunity and Forecast, By By Type, 2016-2032
- 7.4.1. APAC Cholera Vaccines Market Analysis by By Type: Introduction
- 7.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Type, 2016-2032
- 7.4.3. Whole Cell V. Cholerae O1 with Recombinant B-Subunit
- 7.4.4. Killed Oral O1 and O139
- 7.5. APAC Cholera Vaccines Market Analysis, Opportunity and Forecast, By By End-Users, 2016-2032
- 7.5.1. APAC Cholera Vaccines Market Analysis by By End-Users: Introduction
- 7.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-Users, 2016-2032
- 7.5.3. Hospitals and Clinics
- 7.5.4. Research and Academic Laboratories
- 7.5.5. Others
- 7.6. APAC Cholera Vaccines Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 7.6.1. APAC Cholera Vaccines Market Analysis by Country : Introduction
- 7.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 7.6.2.1. China
- 7.6.2.2. Japan
- 7.6.2.3. South Korea
- 7.6.2.4. India
- 7.6.2.5. Australia & New Zeland
- 7.6.2.6. Indonesia
- 7.6.2.7. Malaysia
- 7.6.2.8. Philippines
- 7.6.2.9. Singapore
- 7.6.2.10. Thailand
- 7.6.2.11. Vietnam
- 7.6.2.12. Rest of APAC
- 8. Latin America Cholera Vaccines Market Analysis, Opportunity and Forecast, 2016-2032
- 8.1. Latin America Cholera Vaccines Market Analysis, 2016-2021
- 8.2. Latin America Cholera Vaccines Market Opportunity and Forecast, 2023-2032
- 8.3. Latin America Cholera Vaccines Market Analysis, Opportunity and Forecast, By By Product, 2016-2032
- 8.3.1. Latin America Cholera Vaccines Market Analysis by By Product: Introduction
- 8.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Product, 2016-2032
- 8.3.3. Dukoral
- 8.3.4. Shanchol
- 8.3.5. Vaxchora
- 8.3.6. Others Products
- 8.4. Latin America Cholera Vaccines Market Analysis, Opportunity and Forecast, By By Type, 2016-2032
- 8.4.1. Latin America Cholera Vaccines Market Analysis by By Type: Introduction
- 8.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Type, 2016-2032
- 8.4.3. Whole Cell V. Cholerae O1 with Recombinant B-Subunit
- 8.4.4. Killed Oral O1 and O139
- 8.5. Latin America Cholera Vaccines Market Analysis, Opportunity and Forecast, By By End-Users, 2016-2032
- 8.5.1. Latin America Cholera Vaccines Market Analysis by By End-Users: Introduction
- 8.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-Users, 2016-2032
- 8.5.3. Hospitals and Clinics
- 8.5.4. Research and Academic Laboratories
- 8.5.5. Others
- 8.6. Latin America Cholera Vaccines Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 8.6.1. Latin America Cholera Vaccines Market Analysis by Country : Introduction
- 8.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 8.6.2.1. Brazil
- 8.6.2.2. Colombia
- 8.6.2.3. Chile
- 8.6.2.4. Argentina
- 8.6.2.5. Costa Rica
- 8.6.2.6. Rest of Latin America
- 9. Middle East & Africa Cholera Vaccines Market Analysis, Opportunity and Forecast, 2016-2032
- 9.1. Middle East & Africa Cholera Vaccines Market Analysis, 2016-2021
- 9.2. Middle East & Africa Cholera Vaccines Market Opportunity and Forecast, 2023-2032
- 9.3. Middle East & Africa Cholera Vaccines Market Analysis, Opportunity and Forecast, By By Product, 2016-2032
- 9.3.1. Middle East & Africa Cholera Vaccines Market Analysis by By Product: Introduction
- 9.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Product, 2016-2032
- 9.3.3. Dukoral
- 9.3.4. Shanchol
- 9.3.5. Vaxchora
- 9.3.6. Others Products
- 9.4. Middle East & Africa Cholera Vaccines Market Analysis, Opportunity and Forecast, By By Type, 2016-2032
- 9.4.1. Middle East & Africa Cholera Vaccines Market Analysis by By Type: Introduction
- 9.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Type, 2016-2032
- 9.4.3. Whole Cell V. Cholerae O1 with Recombinant B-Subunit
- 9.4.4. Killed Oral O1 and O139
- 9.5. Middle East & Africa Cholera Vaccines Market Analysis, Opportunity and Forecast, By By End-Users, 2016-2032
- 9.5.1. Middle East & Africa Cholera Vaccines Market Analysis by By End-Users: Introduction
- 9.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-Users, 2016-2032
- 9.5.3. Hospitals and Clinics
- 9.5.4. Research and Academic Laboratories
- 9.5.5. Others
- 9.6. Middle East & Africa Cholera Vaccines Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 9.6.1. Middle East & Africa Cholera Vaccines Market Analysis by Country : Introduction
- 9.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 9.6.2.1. Algeria
- 9.6.2.2. Egypt
- 9.6.2.3. Israel
- 9.6.2.4. Kuwait
- 9.6.2.5. Nigeria
- 9.6.2.6. Saudi Arabia
- 9.6.2.7. South Africa
- 9.6.2.8. Turkey
- 9.6.2.9. The UAE
- 9.6.2.10. Rest of MEA
- 10. Global Cholera Vaccines Market Analysis, Opportunity and Forecast, By Region , 2016-2032
- 10.1. Global Cholera Vaccines Market Analysis by Region : Introduction
- 10.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Region , 2016-2032
- 10.2.1. North America
- 10.2.2. Western Europe
- 10.2.3. Eastern Europe
- 10.2.4. APAC
- 10.2.5. Latin America
- 10.2.6. Middle East & Africa
- 11. Global Cholera Vaccines Market Competitive Landscape, Market Share Analysis, and Company Profiles
- 11.1. Market Share Analysis
- 11.2. Company Profiles
- 11.3. GSK plc (U.K.)
- 11.3.1. Company Overview
- 11.3.2. Financial Highlights
- 11.3.3. Product Portfolio
- 11.3.4. SWOT Analysis
- 11.3.5. Key Strategies and Developments
- 11.4. Valneva SE. (France)
- 11.4.1. Company Overview
- 11.4.2. Financial Highlights
- 11.4.3. Product Portfolio
- 11.4.4. SWOT Analysis
- 11.4.5. Key Strategies and Developments
- 11.5. EMERGENT (U.S.)
- 11.5.1. Company Overview
- 11.5.2. Financial Highlights
- 11.5.3. Product Portfolio
- 11.5.4. SWOT Analysis
- 11.5.5. Key Strategies and Developments
- 11.6. Astellas Pharma Inc.(Japan)
- 11.6.1. Company Overview
- 11.6.2. Financial Highlights
- 11.6.3. Product Portfolio
- 11.6.4. SWOT Analysis
- 11.6.5. Key Strategies and Developments
- 11.7. Sanofi (France)
- 11.7.1. Company Overview
- 11.7.2. Financial Highlights
- 11.7.3. Product Portfolio
- 11.7.4. SWOT Analysis
- 11.7.5. Key Strategies and Developments
- 11.8. EUBIOLOGICS CO., LTD (South Korea)
- 11.8.1. Company Overview
- 11.8.2. Financial Highlights
- 11.8.3. Product Portfolio
- 11.8.4. SWOT Analysis
- 11.8.5. Key Strategies and Developments
- 11.9. Johnson & Johnson Services Inc. (India)
- 11.9.1. Company Overview
- 11.9.2. Financial Highlights
- 11.9.3. Product Portfolio
- 11.9.4. SWOT Analysis
- 11.9.5. Key Strategies and Developments
- 11.10. Celldex Therapeutics. (U.S.)
- 11.10.1. Company Overview
- 11.10.2. Financial Highlights
- 11.10.3. Product Portfolio
- 11.10.4. SWOT Analysis
- 11.10.5. Key Strategies and Developments
- 11.11. Merck & Co., Inc. (U.S.)
- 11.11.1. Company Overview
- 11.11.2. Financial Highlights
- 11.11.3. Product Portfolio
- 11.11.4. SWOT Analysis
- 11.11.5. Key Strategies and Developments
- 11.12. Other Key Players
- 11.12.1. Company Overview
- 11.12.2. Financial Highlights
- 11.12.3. Product Portfolio
- 11.12.4. SWOT Analysis
- 11.12.5. Key Strategies and Developments
- 12. Assumptions and Acronyms
- 13. Research Methodology
- 14. Contact
- List of Figures
- Figure 1: Global Cholera Vaccines Market Revenue (US$ Mn) Market Share by By Product in 2022
- Figure 2: Global Cholera Vaccines Market Attractiveness Analysis by By Product, 2016-2032
- Figure 3: Global Cholera Vaccines Market Revenue (US$ Mn) Market Share by By Typein 2022
- Figure 4: Global Cholera Vaccines Market Attractiveness Analysis by By Type, 2016-2032
- Figure 5: Global Cholera Vaccines Market Revenue (US$ Mn) Market Share by By End-Usersin 2022
- Figure 6: Global Cholera Vaccines Market Attractiveness Analysis by By End-Users, 2016-2032
- Figure 7: Global Cholera Vaccines Market Revenue (US$ Mn) Market Share by Region in 2022
- Figure 8: Global Cholera Vaccines Market Attractiveness Analysis by Region, 2016-2032
- Figure 9: Global Cholera Vaccines Market Revenue (US$ Mn) (2016-2032)
- Figure 10: Global Cholera Vaccines Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Figure 11: Global Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Figure 12: Global Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Figure 13: Global Cholera Vaccines Market Revenue (US$ Mn) Comparison by By End-Users (2016-2032)
- Figure 14: Global Cholera Vaccines Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
- Figure 15: Global Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Figure 16: Global Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Figure 17: Global Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By End-Users (2016-2032)
- Figure 18: Global Cholera Vaccines Market Share Comparison by Region (2016-2032)
- Figure 19: Global Cholera Vaccines Market Share Comparison by By Product (2016-2032)
- Figure 20: Global Cholera Vaccines Market Share Comparison by By Type (2016-2032)
- Figure 21: Global Cholera Vaccines Market Share Comparison by By End-Users (2016-2032)
- Figure 22: North America Cholera Vaccines Market Revenue (US$ Mn) Market Share by By Productin 2022
- Figure 23: North America Cholera Vaccines Market Attractiveness Analysis by By Product, 2016-2032
- Figure 24: North America Cholera Vaccines Market Revenue (US$ Mn) Market Share by By Typein 2022
- Figure 25: North America Cholera Vaccines Market Attractiveness Analysis by By Type, 2016-2032
- Figure 26: North America Cholera Vaccines Market Revenue (US$ Mn) Market Share by By End-Usersin 2022
- Figure 27: North America Cholera Vaccines Market Attractiveness Analysis by By End-Users, 2016-2032
- Figure 28: North America Cholera Vaccines Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 29: North America Cholera Vaccines Market Attractiveness Analysis by Country, 2016-2032
- Figure 30: North America Cholera Vaccines Market Revenue (US$ Mn) (2016-2032)
- Figure 31: North America Cholera Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 32: North America Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Figure 33: North America Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Figure 34: North America Cholera Vaccines Market Revenue (US$ Mn) Comparison by By End-Users (2016-2032)
- Figure 35: North America Cholera Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 36: North America Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Figure 37: North America Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Figure 38: North America Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By End-Users (2016-2032)
- Figure 39: North America Cholera Vaccines Market Share Comparison by Country (2016-2032)
- Figure 40: North America Cholera Vaccines Market Share Comparison by By Product (2016-2032)
- Figure 41: North America Cholera Vaccines Market Share Comparison by By Type (2016-2032)
- Figure 42: North America Cholera Vaccines Market Share Comparison by By End-Users (2016-2032)
- Figure 43: Western Europe Cholera Vaccines Market Revenue (US$ Mn) Market Share by By Productin 2022
- Figure 44: Western Europe Cholera Vaccines Market Attractiveness Analysis by By Product, 2016-2032
- Figure 45: Western Europe Cholera Vaccines Market Revenue (US$ Mn) Market Share by By Typein 2022
- Figure 46: Western Europe Cholera Vaccines Market Attractiveness Analysis by By Type, 2016-2032
- Figure 47: Western Europe Cholera Vaccines Market Revenue (US$ Mn) Market Share by By End-Usersin 2022
- Figure 48: Western Europe Cholera Vaccines Market Attractiveness Analysis by By End-Users, 2016-2032
- Figure 49: Western Europe Cholera Vaccines Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 50: Western Europe Cholera Vaccines Market Attractiveness Analysis by Country, 2016-2032
- Figure 51: Western Europe Cholera Vaccines Market Revenue (US$ Mn) (2016-2032)
- Figure 52: Western Europe Cholera Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 53: Western Europe Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Figure 54: Western Europe Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Figure 55: Western Europe Cholera Vaccines Market Revenue (US$ Mn) Comparison by By End-Users (2016-2032)
- Figure 56: Western Europe Cholera Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 57: Western Europe Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Figure 58: Western Europe Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Figure 59: Western Europe Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By End-Users (2016-2032)
- Figure 60: Western Europe Cholera Vaccines Market Share Comparison by Country (2016-2032)
- Figure 61: Western Europe Cholera Vaccines Market Share Comparison by By Product (2016-2032)
- Figure 62: Western Europe Cholera Vaccines Market Share Comparison by By Type (2016-2032)
- Figure 63: Western Europe Cholera Vaccines Market Share Comparison by By End-Users (2016-2032)
- Figure 64: Eastern Europe Cholera Vaccines Market Revenue (US$ Mn) Market Share by By Productin 2022
- Figure 65: Eastern Europe Cholera Vaccines Market Attractiveness Analysis by By Product, 2016-2032
- Figure 66: Eastern Europe Cholera Vaccines Market Revenue (US$ Mn) Market Share by By Typein 2022
- Figure 67: Eastern Europe Cholera Vaccines Market Attractiveness Analysis by By Type, 2016-2032
- Figure 68: Eastern Europe Cholera Vaccines Market Revenue (US$ Mn) Market Share by By End-Usersin 2022
- Figure 69: Eastern Europe Cholera Vaccines Market Attractiveness Analysis by By End-Users, 2016-2032
- Figure 70: Eastern Europe Cholera Vaccines Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 71: Eastern Europe Cholera Vaccines Market Attractiveness Analysis by Country, 2016-2032
- Figure 72: Eastern Europe Cholera Vaccines Market Revenue (US$ Mn) (2016-2032)
- Figure 73: Eastern Europe Cholera Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 74: Eastern Europe Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Figure 75: Eastern Europe Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Figure 76: Eastern Europe Cholera Vaccines Market Revenue (US$ Mn) Comparison by By End-Users (2016-2032)
- Figure 77: Eastern Europe Cholera Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 78: Eastern Europe Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Figure 79: Eastern Europe Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Figure 80: Eastern Europe Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By End-Users (2016-2032)
- Figure 81: Eastern Europe Cholera Vaccines Market Share Comparison by Country (2016-2032)
- Figure 82: Eastern Europe Cholera Vaccines Market Share Comparison by By Product (2016-2032)
- Figure 83: Eastern Europe Cholera Vaccines Market Share Comparison by By Type (2016-2032)
- Figure 84: Eastern Europe Cholera Vaccines Market Share Comparison by By End-Users (2016-2032)
- Figure 85: APAC Cholera Vaccines Market Revenue (US$ Mn) Market Share by By Productin 2022
- Figure 86: APAC Cholera Vaccines Market Attractiveness Analysis by By Product, 2016-2032
- Figure 87: APAC Cholera Vaccines Market Revenue (US$ Mn) Market Share by By Typein 2022
- Figure 88: APAC Cholera Vaccines Market Attractiveness Analysis by By Type, 2016-2032
- Figure 89: APAC Cholera Vaccines Market Revenue (US$ Mn) Market Share by By End-Usersin 2022
- Figure 90: APAC Cholera Vaccines Market Attractiveness Analysis by By End-Users, 2016-2032
- Figure 91: APAC Cholera Vaccines Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 92: APAC Cholera Vaccines Market Attractiveness Analysis by Country, 2016-2032
- Figure 93: APAC Cholera Vaccines Market Revenue (US$ Mn) (2016-2032)
- Figure 94: APAC Cholera Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 95: APAC Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Figure 96: APAC Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Figure 97: APAC Cholera Vaccines Market Revenue (US$ Mn) Comparison by By End-Users (2016-2032)
- Figure 98: APAC Cholera Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 99: APAC Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Figure 100: APAC Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Figure 101: APAC Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By End-Users (2016-2032)
- Figure 102: APAC Cholera Vaccines Market Share Comparison by Country (2016-2032)
- Figure 103: APAC Cholera Vaccines Market Share Comparison by By Product (2016-2032)
- Figure 104: APAC Cholera Vaccines Market Share Comparison by By Type (2016-2032)
- Figure 105: APAC Cholera Vaccines Market Share Comparison by By End-Users (2016-2032)
- Figure 106: Latin America Cholera Vaccines Market Revenue (US$ Mn) Market Share by By Productin 2022
- Figure 107: Latin America Cholera Vaccines Market Attractiveness Analysis by By Product, 2016-2032
- Figure 108: Latin America Cholera Vaccines Market Revenue (US$ Mn) Market Share by By Typein 2022
- Figure 109: Latin America Cholera Vaccines Market Attractiveness Analysis by By Type, 2016-2032
- Figure 110: Latin America Cholera Vaccines Market Revenue (US$ Mn) Market Share by By End-Usersin 2022
- Figure 111: Latin America Cholera Vaccines Market Attractiveness Analysis by By End-Users, 2016-2032
- Figure 112: Latin America Cholera Vaccines Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 113: Latin America Cholera Vaccines Market Attractiveness Analysis by Country, 2016-2032
- Figure 114: Latin America Cholera Vaccines Market Revenue (US$ Mn) (2016-2032)
- Figure 115: Latin America Cholera Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 116: Latin America Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Figure 117: Latin America Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Figure 118: Latin America Cholera Vaccines Market Revenue (US$ Mn) Comparison by By End-Users (2016-2032)
- Figure 119: Latin America Cholera Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 120: Latin America Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Figure 121: Latin America Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Figure 122: Latin America Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By End-Users (2016-2032)
- Figure 123: Latin America Cholera Vaccines Market Share Comparison by Country (2016-2032)
- Figure 124: Latin America Cholera Vaccines Market Share Comparison by By Product (2016-2032)
- Figure 125: Latin America Cholera Vaccines Market Share Comparison by By Type (2016-2032)
- Figure 126: Latin America Cholera Vaccines Market Share Comparison by By End-Users (2016-2032)
- Figure 127: Middle East & Africa Cholera Vaccines Market Revenue (US$ Mn) Market Share by By Productin 2022
- Figure 128: Middle East & Africa Cholera Vaccines Market Attractiveness Analysis by By Product, 2016-2032
- Figure 129: Middle East & Africa Cholera Vaccines Market Revenue (US$ Mn) Market Share by By Typein 2022
- Figure 130: Middle East & Africa Cholera Vaccines Market Attractiveness Analysis by By Type, 2016-2032
- Figure 131: Middle East & Africa Cholera Vaccines Market Revenue (US$ Mn) Market Share by By End-Usersin 2022
- Figure 132: Middle East & Africa Cholera Vaccines Market Attractiveness Analysis by By End-Users, 2016-2032
- Figure 133: Middle East & Africa Cholera Vaccines Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 134: Middle East & Africa Cholera Vaccines Market Attractiveness Analysis by Country, 2016-2032
- Figure 135: Middle East & Africa Cholera Vaccines Market Revenue (US$ Mn) (2016-2032)
- Figure 136: Middle East & Africa Cholera Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 137: Middle East & Africa Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Figure 138: Middle East & Africa Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Figure 139: Middle East & Africa Cholera Vaccines Market Revenue (US$ Mn) Comparison by By End-Users (2016-2032)
- Figure 140: Middle East & Africa Cholera Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 141: Middle East & Africa Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Figure 142: Middle East & Africa Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Figure 143: Middle East & Africa Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By End-Users (2016-2032)
- Figure 144: Middle East & Africa Cholera Vaccines Market Share Comparison by Country (2016-2032)
- Figure 145: Middle East & Africa Cholera Vaccines Market Share Comparison by By Product (2016-2032)
- Figure 146: Middle East & Africa Cholera Vaccines Market Share Comparison by By Type (2016-2032)
- Figure 147: Middle East & Africa Cholera Vaccines Market Share Comparison by By End-Users (2016-2032)
List of Tables
- Table 1: Global Cholera Vaccines Market Comparison by By Product (2016-2032)
- Table 2: Global Cholera Vaccines Market Comparison by By Type (2016-2032)
- Table 3: Global Cholera Vaccines Market Comparison by By End-Users (2016-2032)
- Table 4: Global Cholera Vaccines Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Table 5: Global Cholera Vaccines Market Revenue (US$ Mn) (2016-2032)
- Table 6: Global Cholera Vaccines Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Table 7: Global Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Table 8: Global Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Table 9: Global Cholera Vaccines Market Revenue (US$ Mn) Comparison by By End-Users (2016-2032)
- Table 10: Global Cholera Vaccines Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
- Table 11: Global Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Table 12: Global Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Table 13: Global Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By End-Users (2016-2032)
- Table 14: Global Cholera Vaccines Market Share Comparison by Region (2016-2032)
- Table 15: Global Cholera Vaccines Market Share Comparison by By Product (2016-2032)
- Table 16: Global Cholera Vaccines Market Share Comparison by By Type (2016-2032)
- Table 17: Global Cholera Vaccines Market Share Comparison by By End-Users (2016-2032)
- Table 18: North America Cholera Vaccines Market Comparison by By Type (2016-2032)
- Table 19: North America Cholera Vaccines Market Comparison by By End-Users (2016-2032)
- Table 20: North America Cholera Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 21: North America Cholera Vaccines Market Revenue (US$ Mn) (2016-2032)
- Table 22: North America Cholera Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 23: North America Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Table 24: North America Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Table 25: North America Cholera Vaccines Market Revenue (US$ Mn) Comparison by By End-Users (2016-2032)
- Table 26: North America Cholera Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 27: North America Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Table 28: North America Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Table 29: North America Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By End-Users (2016-2032)
- Table 30: North America Cholera Vaccines Market Share Comparison by Country (2016-2032)
- Table 31: North America Cholera Vaccines Market Share Comparison by By Product (2016-2032)
- Table 32: North America Cholera Vaccines Market Share Comparison by By Type (2016-2032)
- Table 33: North America Cholera Vaccines Market Share Comparison by By End-Users (2016-2032)
- Table 34: Western Europe Cholera Vaccines Market Comparison by By Product (2016-2032)
- Table 35: Western Europe Cholera Vaccines Market Comparison by By Type (2016-2032)
- Table 36: Western Europe Cholera Vaccines Market Comparison by By End-Users (2016-2032)
- Table 37: Western Europe Cholera Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 38: Western Europe Cholera Vaccines Market Revenue (US$ Mn) (2016-2032)
- Table 39: Western Europe Cholera Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 40: Western Europe Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Table 41: Western Europe Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Table 42: Western Europe Cholera Vaccines Market Revenue (US$ Mn) Comparison by By End-Users (2016-2032)
- Table 43: Western Europe Cholera Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 44: Western Europe Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Table 45: Western Europe Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Table 46: Western Europe Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By End-Users (2016-2032)
- Table 47: Western Europe Cholera Vaccines Market Share Comparison by Country (2016-2032)
- Table 48: Western Europe Cholera Vaccines Market Share Comparison by By Product (2016-2032)
- Table 49: Western Europe Cholera Vaccines Market Share Comparison by By Type (2016-2032)
- Table 50: Western Europe Cholera Vaccines Market Share Comparison by By End-Users (2016-2032)
- Table 51: Eastern Europe Cholera Vaccines Market Comparison by By Product (2016-2032)
- Table 52: Eastern Europe Cholera Vaccines Market Comparison by By Type (2016-2032)
- Table 53: Eastern Europe Cholera Vaccines Market Comparison by By End-Users (2016-2032)
- Table 54: Eastern Europe Cholera Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 55: Eastern Europe Cholera Vaccines Market Revenue (US$ Mn) (2016-2032)
- Table 56: Eastern Europe Cholera Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 57: Eastern Europe Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Table 58: Eastern Europe Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Table 59: Eastern Europe Cholera Vaccines Market Revenue (US$ Mn) Comparison by By End-Users (2016-2032)
- Table 60: Eastern Europe Cholera Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 61: Eastern Europe Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Table 62: Eastern Europe Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Table 63: Eastern Europe Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By End-Users (2016-2032)
- Table 64: Eastern Europe Cholera Vaccines Market Share Comparison by Country (2016-2032)
- Table 65: Eastern Europe Cholera Vaccines Market Share Comparison by By Product (2016-2032)
- Table 66: Eastern Europe Cholera Vaccines Market Share Comparison by By Type (2016-2032)
- Table 67: Eastern Europe Cholera Vaccines Market Share Comparison by By End-Users (2016-2032)
- Table 68: APAC Cholera Vaccines Market Comparison by By Product (2016-2032)
- Table 69: APAC Cholera Vaccines Market Comparison by By Type (2016-2032)
- Table 70: APAC Cholera Vaccines Market Comparison by By End-Users (2016-2032)
- Table 71: APAC Cholera Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 72: APAC Cholera Vaccines Market Revenue (US$ Mn) (2016-2032)
- Table 73: APAC Cholera Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 74: APAC Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Table 75: APAC Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Table 76: APAC Cholera Vaccines Market Revenue (US$ Mn) Comparison by By End-Users (2016-2032)
- Table 77: APAC Cholera Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 78: APAC Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Table 79: APAC Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Table 80: APAC Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By End-Users (2016-2032)
- Table 81: APAC Cholera Vaccines Market Share Comparison by Country (2016-2032)
- Table 82: APAC Cholera Vaccines Market Share Comparison by By Product (2016-2032)
- Table 83: APAC Cholera Vaccines Market Share Comparison by By Type (2016-2032)
- Table 84: APAC Cholera Vaccines Market Share Comparison by By End-Users (2016-2032)
- Table 85: Latin America Cholera Vaccines Market Comparison by By Product (2016-2032)
- Table 86: Latin America Cholera Vaccines Market Comparison by By Type (2016-2032)
- Table 87: Latin America Cholera Vaccines Market Comparison by By End-Users (2016-2032)
- Table 88: Latin America Cholera Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 89: Latin America Cholera Vaccines Market Revenue (US$ Mn) (2016-2032)
- Table 90: Latin America Cholera Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 91: Latin America Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Table 92: Latin America Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Table 93: Latin America Cholera Vaccines Market Revenue (US$ Mn) Comparison by By End-Users (2016-2032)
- Table 94: Latin America Cholera Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 95: Latin America Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Table 96: Latin America Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Table 97: Latin America Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By End-Users (2016-2032)
- Table 98: Latin America Cholera Vaccines Market Share Comparison by Country (2016-2032)
- Table 99: Latin America Cholera Vaccines Market Share Comparison by By Product (2016-2032)
- Table 100: Latin America Cholera Vaccines Market Share Comparison by By Type (2016-2032)
- Table 101: Latin America Cholera Vaccines Market Share Comparison by By End-Users (2016-2032)
- Table 102: Middle East & Africa Cholera Vaccines Market Comparison by By Product (2016-2032)
- Table 103: Middle East & Africa Cholera Vaccines Market Comparison by By Type (2016-2032)
- Table 104: Middle East & Africa Cholera Vaccines Market Comparison by By End-Users (2016-2032)
- Table 105: Middle East & Africa Cholera Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 106: Middle East & Africa Cholera Vaccines Market Revenue (US$ Mn) (2016-2032)
- Table 107: Middle East & Africa Cholera Vaccines Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 108: Middle East & Africa Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Table 109: Middle East & Africa Cholera Vaccines Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Table 110: Middle East & Africa Cholera Vaccines Market Revenue (US$ Mn) Comparison by By End-Users (2016-2032)
- Table 111: Middle East & Africa Cholera Vaccines Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 112: Middle East & Africa Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Table 113: Middle East & Africa Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Table 114: Middle East & Africa Cholera Vaccines Market Y-o-Y Growth Rate Comparison by By End-Users (2016-2032)
- Table 115: Middle East & Africa Cholera Vaccines Market Share Comparison by Country (2016-2032)
- Table 116: Middle East & Africa Cholera Vaccines Market Share Comparison by By Product (2016-2032)
- Table 117: Middle East & Africa Cholera Vaccines Market Share Comparison by By Type (2016-2032)
- Table 118: Middle East & Africa Cholera Vaccines Market Share Comparison by By End-Users (2016-2032)
- 1. Executive Summary
-
- GSK plc (U.K.)
- Valneva SE. (France)
- EMERGENT (U.S.)
- Astellas Pharma Inc.(Japan)
- Sanofi (France)
- EUBIOLOGICS CO., LTD (South Korea)
- Johnson & Johnson Services Inc. (India)
- Celldex Therapeutics. (U.S.)
- Merck & Co., Inc. (U.S.)
- Other Key Players
Our Clients
View Our Licence Options
